Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 12 Oct, 12:09 UTC

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.